Poster
Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
Author
Yasir Y. Elamin
Condition
NSCLC
Drug target
EGFR L858R
Drug moa
EGFR TKI targeting EGFR activating mutations and resistance mutations
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AACR-2023-BLU-945-EGFR-NSCLC-Late-Breaking-Poster-Presentation.pdf
3 organizations
1 product
Product
BLU-945Organization
Blueprint MedicinesOrganization
Guardant Health